Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ALUMIS INC. | President, CEO and Chairman, Director | Stock Option (Right to Buy) | 246K | Jul 1, 2024 | Direct | ||
ALUMIS INC. | President, CEO and Chairman, Director | Common Stock | 90.8K | Jul 1, 2024 | By Trust | ||
89bio, Inc. | Director | Stock Option (Right to Buy) | 67.7K | May 2, 2024 | Direct | ||
Neoleukin Therapeutics, Inc. | Director | Stock Option (Right to Buy) | 25K | Jun 8, 2023 | Direct | ||
Prelude Therapeutics Inc | Director | Director Stock Option (Right to Buy) | 23.5K | Jun 14, 2024 | Direct | ||
ALUMIS INC. | President, CEO and Chairman, Director | Class A Common Stock | 0 | Jul 1, 2024 | By Trust |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ALMS | ALUMIS INC. | Jun 27, 2024 | 21 | $0 | 4 | Jul 1, 2024 | President, CEO and Chairman, Director |
ALMS | ALUMIS INC. | Jun 27, 2024 | 0 | $0 | 3 | Jun 27, 2024 | President, CEO and Chairman, Director |
PRLD | Prelude Therapeutics Inc | Jun 14, 2024 | 1 | $0 | 4 | Jun 18, 2024 | Director |
ETNB | 89bio, Inc. | May 2, 2024 | 1 | $0 | 4 | May 3, 2024 | Director |
ETNB | 89bio, Inc. | Apr 13, 2024 | 0 | $0 | 3 | Apr 23, 2024 | Director |
PRLD | Prelude Therapeutics Inc | Jun 16, 2023 | 1 | $0 | 4 | Jun 21, 2023 | Director |
NLTX | Neoleukin Therapeutics, Inc. | Jun 8, 2023 | 1 | $0 | 4 | Jun 9, 2023 | Director |
PRLD | Prelude Therapeutics Inc | Jun 17, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Director |
NLTX | Neoleukin Therapeutics, Inc. | May 12, 2022 | 1 | $0 | 4 | May 16, 2022 | Director |
PRLD | Prelude Therapeutics Inc | Jul 19, 2021 | 1 | $0 | 4 | Jul 20, 2021 | Director |
PRLD | Prelude Therapeutics Inc | Jul 19, 2021 | 0 | $0 | 3 | Jul 20, 2021 | Director |
NLTX | Neoleukin Therapeutics, Inc. | May 11, 2021 | 1 | $0 | 4 | May 13, 2021 | Director |